For example, the clinical trial on sulforaphane in chronic obstructive pulmonary disease showed that it did not stimulate the expression of NRF2 target genes when administered orally.4 Other formulations, e.g. inhalable formulations, may be more effective than oral administration. This evidence concerns the gene NFE2L2 and chronic obstructive pulmonary disease.